Trevi Therapeutics ( (TRVI) ) has released its Q3 earnings. Here is a breakdown of the information Trevi Therapeutics presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio™, an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough.
In its third-quarter 2025 financial report, Trevi Therapeutics announced its plans to initiate a comprehensive Phase 3 program for chronic cough in IPF patients by the first half of 2026. The company ended the quarter with $194.9 million in cash and marketable securities, projecting a cash runway extending into 2028.
Key highlights from the report include the successful completion of a Phase 1 drug-drug interaction study and positive safety reviews from the TIDAL study. The company is preparing for an End-of-Phase 2 meeting with the FDA, reflecting its strategic focus on advancing Haduvio for chronic cough conditions that currently lack approved therapies.
Financially, Trevi reported a net loss of $11.8 million for the third quarter, a slight improvement from the $13.2 million loss in the same period last year. R&D expenses decreased due to reduced clinical development costs, while G&A expenses rose due to increased professional fees and personnel costs.
Looking ahead, Trevi Therapeutics remains committed to advancing its clinical programs and engaging with regulatory authorities to address the unmet needs in chronic cough treatment, with a clear path for growth outlined by its management.